Tumor cells evade immunosurveillance by elements of the innate immune system, such as natural killer (NK) cells, by downregulating or 'shedding' certain cell-surface molecules like mouse UL16-binding protein-like transcript 1 (MULT1) that can activate NK cells through NK cell receptors such as NKG2D; they also avoid Fas-mediated apoptosis by downregulating its expression. In the present study we report the design and evaluation of the antitumor activity of a novel fusion protein, MULT1E/FasTI, consisting of the extracellular domain of MULT1 and the transmembrane and intracellular domains of Fas. The fusion construct (pMULT1E/FasTI) was transfected into the mouse pulmonary carcinoma cell line TC-1; and stable cell clones expressing the fusion protein were established. In-vitro cell culture studies demonstrated that the binding of the NKG2D/Fc, a recombinant protein of mouse NK cell receptor, to MULT1E/FasTI expressed on tumor cells was able to elicit apoptosis as assayed by Annexin V-fluorescein isothiocyanate staining and caspase-3 enzyme-linked immunosorbent assay and to activate NKG2D-expressing cells, such as NK cells. In-vivo subcutaneous tumor studies demonstrated that tumor cells expressing MULT1E/FasTI grew significantly slower than cells without the protein. Pulmonary metastasis studies showed that most of the mice completely rejected tumor cells expressing MULT1E/FasTI. This approach may generate a new therapeutic agent for tumor treatment when combined with tumor cell-specific gene delivery vehicles such as oncolytic adenovirus vectors.
Introduction
Natural killer (NK) cells are large granular bone marrowderived lymphocytes serving as an important component of the innate immunity. They act as a 'rapid force' that attack virally infected, transformed and/or tumor cells. [1] [2] [3] NK cells respond faster than T and B cells as they do not have to rearrange the T-cell receptor or the immunoglobulin genes to create a highly diverse repertoire of specificities. Instead, NK cells recognize the target cells by employing 'missing-self recognition'. 4 NK cell function is controlled by a balance of NK cell inhibitory and activating signals. Three inhibitory receptor families have been identified in mice and humans. [5] [6] [7] NK cell inhibitory receptors bind to self-MHC (major histocompatibility complex) class I molecules, and this binding results in profound inhibition of the NK cell. 8 A wide variety of NK cell-activating receptors have also been found, such as NKG2A, NKG2C, NKG2D and NKG2E. NKG2A/C/E, which are type-2 transmembrane receptors with sequence similarities to C-type lectins with highly related sequence, may be present as heterodimers with another protein (CD94) and recognize a nonclassical MHC class 1 molecule known as human leukocyte antigen-E (in humans) or Qa1 (in mice). 9 NKG2D, in contrast, is a homodimeric C-type lectin-like protein that is expressed by all NK cells, subsets of NKT and g-d T cells. [10] [11] [12] After stimulation, virtually all mouse CD8+ T cells and macrophages also express NKG2D. 11, 12 Several distinct ligands for NKG2D have been identified. Human NKG2D ligands include MHC class 1 chain-related protein A (MICA), MICB, ULBP and RAET1. 10 Mouse NKG2D ligands include retinoic acid early transcript 1 (Rae1), histocompatibility 60 (H60) 13 and mouse UL16-binding protein-like transcript 1 (MULT1). 14, 15 Fas (CD95) is a transmembrane cell-surface death receptor that belongs to the tumor necrosis factor (TNF) receptor superfamily. Fas contains three cysteine-rich extracellular domains at the N-terminus, which are responsible for ligand binding, the transmembrane domain, and an intracellular death domain (DD) of about 80 amino acids that is essential for transducing the apoptotic signals. 16 Binding of FasL (CD95L) to Fas receptor results in aggregation of the receptor molecules and recruitment of the adapter molecule, Fas-associated death domain (FADD), through DD-DD interactions. FADD also has another domain called the death-effector domain, which recruits pro-caspase-8 and/or procaspase-10 to the receptor, resulting in formation of a multimeric protein complex called the death-inducing signaling complex (DISC). 16 DISC activates effector caspases such as caspase-3 that in turn cleave a restricted set of target proteins and are responsible for apoptosis in the cell. 17 Tumor cells have developed many strategies for escaping immune surveillance. One of these strategies is to shed NKG2D ligands such as MICA. 18, 19 Shedding of these ligands reduces their surface levels and affects the susceptibility to NKG2D-mediated cytolysis by NK cells. Tumor cells can also escape from Fas-mediated apoptosis by decreasing surface expression of Fas, 20, 21 secreting an antagonistic 'decoy' receptor, 22 expressing anti-apoptotic molecules such as BCL2 family members, 23, 24 downregulating and mutating pro-apoptotic genes such as BAX, APAF1 or Fas. [25] [26] [27] [28] In the present study, we intended to combine the NK cell-mediated cytolysis and Fas-mediated apoptosis into one fusion protein by using the extracellular domain of MULT1 and the transmembrane and intracellular domains of Fas in a mouse model. We hypothesized that the engagement of NK cells and/or other immune cells with tumor cells expressing the fusion protein will not only send an apoptotic signal to the tumor cells but also activate the NK cells through the NKG2D receptor so that not only the engaged tumor cells will be killed via Fas-induced mechanisms but also may be lysed directly by the activated NK cells. The results demonstrate that this fusion protein is functioning as expected.
Results

Expression of MULT1E/FasTI
TC-1 cells were transfected with pMULT1E/FasTI ( Figure 1 ). Clones that were zeocin resistant were selected and labeled as L-5, L-7 and L-10. An in vitro cell growth study shows that all the clones grow at a similar rate (data not shown). The cells of these clones were stained with anti-mouse MULT1 antibody and analyzed by fluorescence-activated cell sorting (FACS). The result showed that TC-1 cells and clone L-7 cells were negative, whereas clones L-5 and L-10 cells were strongly positive (Figure 2a ). To confirm that MULT1E of the fusion protein can indeed bind to NKG2D, the cells were incubated with NKG2D/Fc and then stained with anti-mouse NKG2D antibody conjugated with fluorescein isothiocyanate (FITC). TC-1 cells and clone L-7 cells were dimly positive, whereas clones L-5 and L-10 cells were strongly positive (Figure 2b ) with L-10 cells the strongest. To further confirm the fusion protein expression, reverse transcriptase (RT)-PCR was performed on RNA samples from these clones using two pairs of primers: the first pair covered only the extracellular domain of MULT1; whereas the second pair covered the entire fusion protein. As Figure 2c 
Fusion protein MULT1E/FasTI is more potent than MULT1 in tumor rejection
Stable clones expressing MULT1E protein anchored on the cell membrane were obtained by transfecting TC-1 cells with vector pDispaly/MULT1E and selection. Two of the clones, C-4 and C5, were chosen in this study and the expression of MULT1E protein on the cell surface was confirmed by FACS analysis (data not shown). Clones C-4 and C-5 together with clone L-10 were used in an in vivo tumor study. Two hundred thousand cells of each clone were i.v. injected into C57BL/6J mice (four mice per group). Four weeks later, the mice were killed and tumor nodules on lungs were counted. As expected, the lungs of mice received TC-1 cells were fully covered by tumors. Although tumor cells expressing MULT1E protein on their surface were significantly rejected, the rejection was not as complete as tumor cells expressing MULT1E/FasTI (Table 1) . [32] [33] [34] resulting in reduced sensitivity of tumor cells to Fas-mediated apoptosis, this resistance to Fasmediated apoptosis protects tumor cells from killing by infiltrating antitumor NK cells and T cells. 35 Shedding of NKG2D ligands by tumor cells has been described as a novel immune escape mechanism. 36 Since NKG2D ligand surface levels critically determine the susceptibility to NKG2D-mediated NK cell lysis, stable expression of NKG2D ligands on tumors would help increase NK cell lysis of tumors. 2 In this study, we enhanced the cell-surface expression of MULT1, one of the mouse NKG2D ligands, by anchoring the extracellular domain of MULT1 on tumor cells using a transmembrane sequence of Fas. We also introduced the DD of Fas in the intracellular domain of the fusion protein One of the key features of the designed fusion protein is to send apoptosis signals into the cells expressing the protein after binding to its ligand, NKG2D. Although we do not have direct evidence supporting that the binding of NKG2D can form DISC inside tumor cells, a clear apoptosis signal is sent to the cells as indicated by the increased caspase-3 activity and increased Annexin V-positive cells after treatment of recombinant NKG2D/Fc (Figure 3) . Data from both Annexin V study and caspase-3 study showed a difference between clone L5 and L-10 with the level of apoptotic cells in clone L-10 higher than that of clone L-5 (Figures 3b and d) , suggesting that the induction of apoptosis by the fusion protein may be dose dependent because the FACS analyses demonstrate a slightly higher-level expression of the fusion protein in clone L-10 than that in clone L-5. In this study, we combined high Annexin V cells and high Annexin V/high PI cells as apoptotic cells. We also analyzed the high PI/low Annexin V cells as necrotic cells (Figure 3c ). Although overall, clone L-10 cells showed more apoptotic cells and more necrotic cells than clone L-5 cells after NKG2D/Fc treatment, the two clones behaved differently before and after NKG2D/Fc treatment. The difference of low PI/high Annexin V cells in clone L-10 before and after treatment was only about 2%, whereas it was about 7% in clone L-5. Perhaps there was more secondary necrosis in clone L-10 than clone L-5.
Increased expression of IFN-g is a key indicator of NK cell activation. 37, 38 To confirm the idea that fusion protein MULT1E/FasTI not only sends apoptotic signals into cells expressing it but also activates immune cells that express receptors for MULT1, NK cells isolated from spleen were co-incubated with cells of TC-1 and clones L-5, L-7 and L-10 and the IFN-g expression was detected by FACS analysis. The IFN-g expression by NK cells cocultured with cells of clones L-5 and L-10 significantly increased compared to those of NK cells co-cultured with cells of TC-1 or clone L-7 ( Figure 4) .
To demonstrate whether fusion protein MULT1E/ FasTI has antitumor activity in vivo, a subcutaneous tumor model and a pulmonary metastatic tumor model were used in this study. In the subcutaneous tumor study, clones L-5 and L-10 grew significantly slower than TC-1 cells or clone L-7 cells (Po0.05 and Po0.001, respectively; Figure 5 ). The reason why clone L-10 grew slower than clone L-5 may be due to the level of the fusion protein expression. The pulmonary metastasis study also confirmed the antitumor activity of fusion protein MULT1E/FasTI. The lungs of mice received i.v. injections of cells of clones L-5 and L-10 were almost clear, whereas lungs from mice received cells of TC-1 or clone L-7 showed many tumors (Figure 6c ). Compared to TC-1 cells, clone L-7 developed less tumors and the total weight of their lungs was smaller. Again this may be due to the slightly higher-level expression of endogenous MULT1 (Figure 2b) . The results show that the fusion protein had a much stronger antitumor effect in the pulmonary metastasis setting than in the subcutaneous setting (Figures 5 and 6 ). The possible explanation for 
MULT1E/FasTI induces tumor cell rejection
HSR Kotturi et al this difference could be due to the less accessibility of NK cells in subcutaneous tumor tissue. This is in agreement with a study demonstrating that NK cells are more effective against blood borne metastasis. 39 Previous studies have shown that tumor cells ectopically expressing NKG2D ligands such as MULT1 are potently rejected by NKG2D-expressing lymphocytes. 40, 41 It is worth to know whether the addition of Fas to the MULT1 protein has additional antitumor effect. Clones expressing MULT1E protein on cell surface were created and studied together with clone L-10. Although the expression of MULT1E on cell surface induced a significant tumor rejection compared to control TC-1 cells, a clear additional antitumor effect was observed when Fas was added to the MULT1 protein ( Table 1) .
The pulmonary metastasis data presented cannot distinguish the following two possibilities: tumor cells expressing the fusion protein are destroyed by NK cells or other NKG2D-expressing cells before implantation or the tumor cells are eradicated by NK cells or other NKG2D-expressing cells after implantation. However, the fact that the pulmonary metastasis results is better than subcutaneous study results may suggest that tumor cells expressing the fusion protein may be easier to be destroyed by NK cells before implantation. Our planned fusion gene delivery by adenovirus vectors would answer the question whether fusion protein MULT1E/FasTI can eradicate implanted tumors.
A significant challenge facing cancer gene therapy is how to specifically deliver tumor-killing genes into *** *** * *** Figure 6 Pulmonary metastatic tumor study. A total of 2 Â 10 5 tumor cells of TC-1 or clones L-5, L-7 and L-10 in 0.5 ml HBSS were i.v. injected into C57BL/6J mice (four mice per group). Four weeks after tumor cell injection, mice were killed and their lungs were dissected (a). The lungs were weighted (b) and the tumor nodules on the lungs were counted (c). *Po0.05; ***Po0.001.
Table 1 MULT1E/FasTI is more potent than MULT1 in tumor rejection
Clones
Lung tumor nodules TC-1 >200, >200, >200, >200 C- 4 7, 1, 6, 5 C-5 4, 7, 2, 4 L-10 0, 0, 0, 0 MULT1E/FasTI induces tumor cell rejection HSR Kotturi et al tumor cells efficiently. The recent development of oncolytic adenovirus opens a new window for cancer gene therapy. 42, 43 It is not only a virus therapy that can specifically target tumor cells, but also a useful gene delivery system. 44 The next step of this study is to use oncolytic adenovirus vectors to systemically deliver the fusion protein MULT1E/FasTI into tumor cells.
In conclusion, a bifunctional chimeric protein containing the extracellular domain of MULT1 and the transmembrane and intracellular domains of Fas is created. Both in vitro and in vivo studies demonstrate its antitumor activity. By combining with an oncolytic adenovirus gene delivery system or other gene delivery systems, this fusion protein may represent a novel and effective approach for cancer therapy.
Materials and methods
Mice and cells
C57BL/6J mice (male or female) at 6-8 weeks of age were purchased from Jackson Laboratories (Bar Harbor, ME, USA) and housed in our pathogen-free animal facilities. The animal experiments were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals (NIH Publication number 85-23) and the institutional guidelines. The mouse lung carcinoma cell line TC-1 (ATCC no. JHU-1) was cultured in RPMI 1640 medium containing 10% fetal bovine serum and 100 mg/ml gentamicin at 37 1C with 5% CO 2 .
Cloning of MULT1 extracellular domain into pcDNA3.1(+)
Thymus glands from 4-day-old newborn C57BL/6J mice were removed and stored in liquid nitrogen. The glands were homogenized using a tissue homogenizer and total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad, CA, USA). Primers were designed for amplification of the extracellular domain of MULT1 (GenBank accession no. NM_029975) from 236 to 868 bp. The sequence of the 5 0 primer is CCCAAGCTTATGGAGCT GACTGCCAGTAACAAGGTCC and that of the 3 0 primer is CGGGATCCGGTACTGAAAGATCCTGCAGG CTCCAG. At the 5 0 end of the upstream primer, a HindIII enzyme site was created and at the 5 0 end of downstream primer, a BamHI site was created. cDNA was synthesized from the extracted total RNA using RT-PCR kit (Promega, Madison, WI, USA). The fragment was excised and gel purified using a gel purification kit (Qiagen, Valencia, CA, USA). Double enzyme digestion was performed on the purified fragment using HindIII and BamHI. The enzyme digested fragment was then ligated into a pcDNA3.1(+) vector (Invitrogen). The full MULT1 cDNA sequence in the new vector, pMULT1E, was confirmed by DNA sequencing. To generate tumor cell clones that express MULT1E on cell surface, the open reading frame of MULT1E cDNA was amplified by PCR and inserted into pDisplay vector (Invitrogen) that has a cell membrane anchor sequence. The new vector is named pDispay/MULT1E.
Cloning of Fas transmembrane and intracellular domains into pcDNA3.1(+)/Zeo
The cDNA clone of the Fas receptor in pDNR-LIB (ATCC no. 10088798) was purchased from American Type Collection Center (ATCC, Manassas, VA, USA). A pair of primers was designed for amplification of the transmembrane and intracellular domains of Fas from 524 to 1013 bp (GenBank accession no. BC061160). The 5 0 primer used was CGGGATCCCCCAGAAATCGCCTAT GGTTGTTGTTGACC and the 3 0 primer was CGGAAT TCTCACTCCAGACATTGTCCTTCATTTTC. At the 5 0 end of the upstream primer, a BamHI enzyme site was created and at the 5 0 end of the downstream primer, an EcoRI enzyme site was created. PCR was performed to amplify the Fas transmembrane and intracellular domains from pDNR-LIB. The gel purified fragment was treated with BamHI and EcoRI enzymes and ligated into the pcDNA3.1(+) vector to create pFasTI. The DNA sequence of the transmembrane and intracellular domains of Fas in vector pFasTI was confirmed by DNA sequencing.
Creation of the vector pMULT1E/FasTI
The cDNA fragment encoding the MULT1 extracellular domain was cut out from pMULT1E by HindIII and BamHI enzyme digestion and ligated into the pFasTI. The resulting vector was named pMULT1E/FasTI ( Figure 1 ) and used for transfection.
Transfection of TC-1 cells
TC-1 mouse lung carcinoma cells were transfected with linearized pMULT1E/FasTI vector using Lipofectamine (Invitrogen) as directed by the manufacturer. To obtain stable clones expressing the fusion protein, the transfected cells were cultured in medium containing 250 mg/ml zeocin. Zeocin-resistant clones were obtained and subcultured in the presence of zeocin.
Fusion protein expression by transfected TC-1 clones
For the analysis of MULT1E/FasTI surface expression, cells from TC-1 and zeocin-resistant clones were gently detached using TrypLE Express (Invitrogen) and washed with staining buffer twice. Five hundred thousand of each clone were incubated with 1 mg monoclonal rat antimouse MULT1 antibody (R&D Systems, Minneapolis, MN, USA) for 30 min at 4 1C. After washing twice with staining buffer, the cells were stained with FITC-labeled goat F(ab') anti-rat IgG antibody for 30 min at 4 1C. After washing twice with staining buffer, cells were resuspended in 0.5 ml staining buffer and analyzed on FACSCalibur (Becton Dickinson, San Jose, CA, USA) using CellQuest software (Becton Dickinson). To confirm that MULT1E expressed as the fusion protein on the transfected cells can indeed bind to NKG2D, cells were first treated with 1 mg/ml of NKG2D/Fc, a recombinant protein of mouse NKG2D (R&D Systems) for 30 min at room temperature (RT), stained with FITC-labeled rat anti-mouse NKG2D antibody and analyzed by FACS. Three clones, L-5, L-7 and L-10 together with TC-1 cells were used for further studies.
RT-PCR
Two million cells of TC1, L-5, L-7 and L10 were used to extract total RNA using TRIzol reagent (Invitrogen). RNA samples were treated with DNase 1 prior to reverse transcription using RQ1 Rnase-Free DNase (Promega). The treated RNAs were then used for RT-PCR using Access Quick RT-PCR system (Promega) according to the manufacturer's protocol. Two different RT-PCR reactions were performed, one for amplifying only 5 cells in triplicates were used for analysis of caspase-3 activity according to the manufacturer's instructions. Briefly, cells were trypsinized, washed with phosphate-buffered saline (PBS) and lysed. The lysates were incubated with caspase-3 substrate for 1 h at 37 1C and the fluorescent signal was detected using a SpectraMax Gemini XS microplate reader (Molecular Devices, Sunnyvale, CA, USA).
Activation of NK cells by MULT1E/FasTI
To test whether the MULT1E/FasTI fusion protein activates NK cells, 1 Â 10 6 cells of TC-1 and clones L-5, L-7 and L-10 were co-cultured for 3 h at a ratio of 1:2 with NK cells isolated from the spleens of female C57BL/6J mice using a mouse NK Cell Isolation Kit (Miltenyi Biotec, Auburn, CA, USA). The NK cells were then recovered and stained with anti-mouse NK1.1 antibody conjugated with FITC (BD Biosciences, San Diego, CA, USA). The cells were then permeabilized and fixed using the Cytofix/Cytoperm Plus (BD Biosciences), stained with anti-mouse IFN-g antibody-phycoerythrin (PE; BD Biosciences) and analyzed by FACS using the CellQuest software for intracellular IFN-g production.
In vivo tumor studies were counted using a dissecting microscope, and tumor weight was also determined by weighing the lungs.
Statistical analysis
GraphPad software (Prism, San Diego, CA, USA) was used to plot graphs. One-way or two-way analysis of variance (ANOVA) with Bonferroni post-tests was used to perform the statistical analyses of the data. Student's t-test was used to analyze the subcutaneous tumor growth data ( Figure 5 ). The significance was represented as *Po0.05; **Po0.01 and ***Po0.001.
